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ABSTRACT
Human tyrosyl-DNA phosphodiesterase (Tdp1) pro-
cesses 30-blocking lesions, predominantly
30-phosphotyrosyl bonds resulting from the trapping
of topoisomerase I (Top1) cleavage complexes. The
controversial ability of yeast Tdp1 to hydrolyze
50-phosphotyrosyl linkage between topoisomerase
II (Top2) and DNA raises the question whether
human Tdp1 possesses 50-end processing activity.
Here we characterize the end-binding and cleavage
preference of human Tdp1 using single-stranded
50- and 30-fluorescein-labeled oligonucleotides. We
establish 30-fluorescein as an efficient surrogate
substrate for human Tdp1, provided it is attached
to the DNA by a phosphodiester (but not a
phosphorothioate) linkage. We demonstrate that
human Tdp1 lacks the ability to hydrolyze a
phosphodiester linked 50-fluorescein. Using both
fluorescence anisotropy and time-resolved fluores-
cence quenching techniques, we also show the pref-
erential binding of human Tdp1 to the 30-end.
However, DNA binding competition experiments
indicate that human Tdp1 binding is dependent on
DNA length rather than number of DNA ends.
Lastly, using surface plasmon resonance, we show
that human Tdp1 selectively binds the 30-end of DNA.
Together, our results suggest human Tdp1 may act
using a scanning mechanism, in which Tdp1 bind
non-specifically upstream of a 30-blocking lesion
and is preferentially stabilized at 30-DNA ends corre-
sponding to its site of action.
INTRODUCTION
DNA strand breaks caused by exogenous and endogenous
sources often contain blocking terminal groups with
abnormal structures that must be initially removed by
DNA end-processing enzymes prior to their repair by
DNA polymerases and sealing by DNA ligases. One
such DNA repair enzyme, tyrosyl-DNA phosphodiester-
ase (Tdp1), catalyzes the hydrolysis of a variety of
30-lesions from DNA resulting in a 30-phosphate product
[for review, see ref. (1)]. Tdp1 eﬃciently processes
30-phosphotyrosyl linkages, which arise from abortive
topoisomerase I (Top1)–DNA cleavage complexes (2–4).
Other physiological Tdp1 substrates include
30-phosphoglycolates (5) and 30-abasic sites (6). In
addition, Tdp1 possesses a 30-nucleosidase activity in
which a single nucleoside is removed from 30-hydroxy
terminated ribo- and deoxyribonucleosides (6). This
non-processive single-base excision is explained by the
fact that 30-phosphate terminated ends are non-
hydrolyzable Tdp1 substrates (6). Such 30-phosphate
ends generated by Tdp1 are eﬃciently removed by poly-
nucleotide kinase 30-phosphatase (PNKP) to produce a
30-hydroxyl, which can then be processed further and
repaired by DNA ligases and polymerases (7–9).
The physiological importance of Tdp1 in DNA repair
stems from the observation that a mutation in the human
TDP1 gene, which results in an active site histidine to
arginine mutation (H493R), has been associated with the
rare neurodegenerative disorder spinocerebellar ataxia
with axonal neuropathy (SCAN1) (10). Lymphoblastoid
cell lines from SCAN1 patients are hypersensitive to both
camptothecin (CPT) and oxidative stress (11–14). In
addition, the recent generation of Tdp1 knockout mice
has further established the involvement of Tdp1 in the
repair of both Top1–DNA adducts and oxidative DNA
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Tdp1
 /  mice to CPT and bleomycin or hydrogen
peroxide, respectively (15,16).
Several non-physiological Tdp1 substrates have also
been identiﬁed including a 30-biotin linked adduct (6)
and a ﬂuorescent 30-(4-methylumbelliferone) reporter
molecule (17) as well as two 30-phosphotyrosine analogs,
30-(4-nitro)phenol and 30-(4-methyl)phenol (17). These
types of substrates have proven useful for measuring
Tdp1 activity and screening for Tdp1 inhibitors (17–19).
In addition, such substrates have a decisive advantage
over the naturally occurring Tdp1 substrates in that they
are more cost-eﬀective.
Discrepancies still remain concerning the 50-end pro-
cessing activity of Tdp1. While Yang et al. initially
showed that partially puriﬁed yeast Tdp1 was unable to
process 50-tyrosine-containing oligonucleotides (2), subse-
quent studies have suggested that recombinant yeast Tdp1
can remove 50-phosphotyrosyl peptides from DNA or
more speciﬁcally topoisomerase II (Top2)-related DNA
adducts (20). Those biochemical results were supported
by the hypersensitivity of yeast tdp1 mutants over-
expressing Top2 to the clinically used Top2 inhibitor,
etoposide (20). It has also been shown that enhanced
expression of human Tdp1 in cultured cells eﬀectively
decreases etoposide-induced Top2-mediated DNA
damage (21). The crystal structures of the yeast (22) and
human (23) Tdp1 proteins show minimal diﬀerences in
active site architecture in spite of large diﬀerences in
amino acid composition, suggesting similar catalytic
mechanisms. However, biochemical data have been
lacking to question the 50-end binding and processing
associated with human Tdp1.
To better understand what determines the 30-end-
speciﬁc recognition and processing activities of human
Tdp1, we have examined the DNA binding and cleavage
properties of human Tdp1 using 50- and 30-ﬂuorescein-
labeled oligonucleotides. We have also analyzed for the
ﬁrst time the binding of human Tdp1 to non-hydrolyzable
30-ends containing a 30-phosphate or a
30-phosphorothioate-linked ﬂuorescein.
MATERIALS AND METHODS
Materials
All DNA oligonucleotides were synthesized by Integrated
DNA Technologies (Coralville, IA, USA) with the excep-
tion of those containing a ﬂuorescein attached via a
phosphorothioate linkage, which were synthesized by
Sigma-Genosys (St Louis, MO, USA). T4 polynucleotide
30-phosphatase (PNK) and the 30-phosphatase minus
mutant T4 PNK [PNK( )] were purchased from New
England BioLabs (Cambridge, MA, USA). Terminal
deoxynucleotidyl transferase (TdT) was purchased from
Calbiochem (La Jolla, CA, USA).
Expression and puriﬁcation of Tdp1
Human Tdp1 was expressed in Escherichia coli BL21
(DE3) cells and puriﬁed as described earlier (18).
Preparation of radiolabeled oligonucleotides
DNA oligonucleotides were either 50-end labeled using
PNK and [g-
32P] ATP or 30-end labeled using TdT
and [a-
32P] cordycepin-50-triphosphate, respectively.
Unincorporated radioactive nucleotides were removed
using a mini Quick Spin Oligo column (Roche
Diagnostics, Indianapolis, IN, USA).
Tdp1 and PNK enzymatic assays
One nanomolar of
32P-labeled oligonucleotide substrate in
a1 0ml reaction volume was incubated with the indicated
concentrations of recombinant Tdp1 for 30min at 25 Ci n
a buﬀer containing 50mM Tris–HCl (pH 7.5), 25mM KCl
and 2mM EDTA. In reactions containing PNK or
PNK( ), the reaction buﬀer was supplemented with
10mM MgCl2. Reactions were terminated by the
addition of two volumes of gel loading buﬀer [96% (v/v)
formamide, 10mM EDTA, 1% (w/v) xylene cyanol and
1% (w/v) bromphenol blue]. The samples were
subsequently heated to 95 C for 5min and subjected to
20% sequencing gel electrophoresis. Imaging was per-
formed using the Typhoon 8600.
Fluorescence anisotropy
Equilibrium binding of Tdp1 to ﬂuorescein (6-FAM)-
labeled oligonucleotides was monitored by ﬂuorescence
anisotropy using previously developed methods (24).
Brieﬂy, serial dilutions of recombinant Tdp1 were mixed
with 10nM of ﬂuorescein-labeled oligonucleotides
(Table 1) in a binding buﬀer containing 50mM Tris–
HCl (pH 7.5), 25mM KCl and 2mM EDTA in a ﬁnal
volume of 50ml. Aliquots (40ml) were transferred into
384-well Costar polypropylene plates (Corning, NY,
USA) and read using a Tecan Ultra plate reader
(Durham, NC, USA) with excitation and emission wave-
lengths of 485 and 535nm, respectively.
Table 1. Sequence, structure, and calculated dissociation constants
(KD) of oligonucleotides used in this study
Name Length
(nt)
Sequence (50–30) KD
(nM)
a
95% Cl
(nM)
14Y 14 GATCTAAAAGACTT-Y NA NA
14F 14 GATCTAAAAGACTT-F NA NA
F14 14 F-GATCTAAAAGACTT 76.9 66.2–87.5
F14p 14 F-GATCTAAAAGACTTp 34.1 26.8–41.4
14p 14 GATCTAAAAGACTTp NA NA
15F 15 GATCTAAAAGACTTG-F NA NA
15(pS)F 15 GATCTAAAAGACTTG(pS)-F 2.4 1.3–3.4
F15 15 F-GATCTAAAAGACTTG 39.2 31.9–46.5
F(pS)15 15 F-(pS)GATCTAAAAGACTTG 26.3 22.6–30.0
p14B 14 pGATCTAAAAGACTT-B NA NA
B14p 14 B-GATCTAAAAGACTTp 57.0 NA
50p 50 AAGATCTAAAAGACTTAAG
GATCTAAAAGACTTGAAG
ATCTAAAAGACTTp
NA NA
Y represents the tyrosyl chemical group (Figure 1A); F represents the
6-FAM chemical group (Figure 1A); B represents the biotin chemical
group; p represents the terminal phosphate; (pS) represents the
phosphorothioate linkage; NA, not applicable.
aSee ‘Materials and Methods’ section for KD calculations.
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A constant concentration of F14p (10nM) was mixed with
2-fold serial dilutions of unlabeled competitor
oligonucleotide in 50mM Tris–HCl (pH 7.5), 25mM
KCl, 2mM EDTA and placed in a 96-well Costar
polypropylene plates (Corning). A constant concentration
of Tdp1 (100nM) was then added to a ﬁnal volume of
50ml and incubated at room temperature for 20min.
Aliquots (40ml) were transferred into 384-well Costar
polypropylene plates (Corning) and read using a Tecan
Ultra plate reader (Durham) with excitation and
emission wavelengths of 485 and 535nm, respectively.
Fluorescence anisotropy data analysis
Equilibrium dissociation constants (KD) were estimated
from the anisotropy in three steps. First, the total intensity
of the ﬂuorophore was examined and a correction
parameter, R, was estimated (25). Next, an equation
relating fractional binding (fB) and anisotropy was
selected [Equation (1)],
Anisotropy ¼
fBrBR þ rFð1   fBÞ
fBR   fB þ 1
1
where fB is fractional binding; rB is anisotropy signal of
saturated binding; rF is anisotropy signal of no binding
and R is ratio of maximum and minimum total
ﬂuorescence intensity.
Finally, the fractional binding model is ﬁt to the
anisotropy signal using a nonlinear least squares algo-
rithm. For this, the simple Langmuir model was selected
[Equation (2)], where KD refers to the dissociation
constant.
fB ¼
½Tdp1free ½DNAfree 
KD½DNAtotal 
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Figure 1. Processing of ﬂuorescein-labeled oligonucleotides by recombinant human Tdp1. (A) Representative denaturing PAGE gel showing
Tdp1-mediated conversion of 50-end radiolabeled 14-mer oligonucleotides containing a 30-tyrosine (p14Y)o r3 0-ﬂuorescein (p14F)t oa3 0-phosphate
product (p14p). The chemical structures of the 30-tyrosine and 30-6-FAM are shown above the gel. (B) Representative denaturing PAGE gel showing
the generation of an unknown product (indicated by question mark) from Tdp1 cleavage of a 30-end radiolabeled 14-mer oligonucleotide containing a
50-ﬂuorescien (F14pA). Tdp1 concentrations in (A) and (B) are as follows: 0.01nM (lanes 2 and 8), 0.1nM (lanes 3 and 9), 1nM (lanes 4 and 10),
10nM (lanes 5 and 11) and 100nM (lanes 6 and 12). (C)3 0-end processing of the F14pA oligonucleotide [from (B)] by the combinations of Tdp1
(100nM) and wild-type T4 PNK [PNK (1 unit), lane 5] or Tdp1 and 30-phosphatase-minus mutant T4 PNK [PNK
  (1 unit), lane 7]. (D)3 0-end
processing of the diﬀerent substrates. (E) Schematic illustrating the substrates and products of the sequential action of Tdp1 and PNK on the F14pA
oligonucleotide. In all instances the asterisk indicates the
32P-labeled phosphate.
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cally. The concentration of DNAfree and Tdp1free were
solved numerically using a conservation law. The system
is then ﬁt to experimental anisotropy data using a
non-linear regression operator based on a Marquardt
compromise. When the KD value is small relative to the
concentration titration range, the binding may be assumed
to be stoichiometric. In this case, a plot of the molar ratio
of the Tdp1 and DNA versus fractional binding will
achieve half saturation binding at a ratio of unity. This
is checked when the DNA binds tight enough for this test
to be completed.
Time resolved ﬂuorescence
Fluorescence lifetimes were measured time-correlated
single-photon counting using a PicoQuant FluoTime200
instrument. The excitation wavelength was 470nm with a
repetition rate of 10MHz. The emission was collected at a
wavelength of 535nm through a 0.5nm band pass under
magic angle conditions. The instrument response signal
was measured with a scattering solution of Ludox. All
measurements were performed at ambient temperature.
Fluorescein-labeled oligonucleotides were prepared in
50mM Tris–HCl (pH 7.5), 25mM KCl and 2mM
EDTA at a concentration of 150nM. Recombinant
Tdp1 was added (37.5–450nM) to each oligonucleotide
and the intensity decay curve was recorded. For each titra-
tion the decay curves were ﬁt globally using the FluoFit
software (PicoQuant) using a bi-exponential function. The
quality of the ﬁts were evaluated by the reduced
chi-squared and randomness of the residuals.
Surface plasmon resonance binding assays
Surface plasmon resonance (SPR) binding experiments
were performed on a Biacore 2000 instrument (GE,
Piscatawy, NJ, USA). Neutravidin was coupled to the
carboxymethylated dextran surface of a CM5 sensor
chip (GE, Piscatawy, NJ, USA) using standard amine
coupling chemistry. In brief, the surface was activated
with 0.1MN-hydroxysuccinimide and 0.4MN-ethyl-N0-
(3-dimethylaminopropyl) carbodiimide at a ﬂow rate of
20ml/min. Neutravidin was diluted to 200mg/ml in 10mM
sodium acetate (pH 4.5) and injected until a density of
 1800 RU was attached. Activated amine groups were
quenched with an injection of 1M ethanolamine (pH 8.0).
50- and 30-biotinylated DNA oligonucleotides (see B14p
and p14B in Table 1) were immobilized to the
neutravidin-coated sensor chips at 37 and 28 RU, respec-
tively. Recombinant Tdp1 was diluted in running buﬀer
[20mM HEPES (pH 7.5), 150mM NaCl, 2mM EDTA,
0.05% (w/v) Tween-20, 5mg/ml carboxymethyl dextran,
0.05% (w/v) polyethylene glycol 20000] in nine successive
2-fold dilutions from 500nM and injected over the
immobilized oligonucleotides for 1min at 20ml/min at
25 C. At the end of the injection, Tdp1-oligonucleotide
complexes were allowed to dissociate for 3min. A 30s
pulse of 1M NaCl removed any material that remained
bound to the surface. Each cycle of Tdp1 injection was
followed by a running buﬀer cycle for referencing
purposes. To ensure the integrity of the oligonucleotide
surface was not compromised by Tdp1 binding, ﬁve injec-
tions of 50nM HIV-1 nucleocapsid protein were made
through the course of the experiment. The binding
kinetics of Tdp1 could not be ﬁt with a simple Langmuir
binding model. However, the equilibrium binding response
wasﬁtwithaLangmuirbindingmodelusingBiaEvaluation
software.
RESULTS
Human Tdp1 can remove ﬂuorescein from the 30-end, but
not the 50-end of DNA
Based on the structural diversity of substrates that are
cleaved by Tdp1 (1,5,6), we reasoned that a ﬂuorescein
molecule could also serve as a convenient and quantitative
probe to investigate the DNA binding and processing of
human Tdp1. To address the end-speciﬁc cleavage
(30 versus 50) of human Tdp1, 14-mer oligonucleotide con-
jugates were synthesized containing the ﬂuorescein deriv-
ative, 6-FAM (chemical structure shown in Figure 1A),
attached via the terminal phosphodiester at the 30-o r
50-end of the oligonucleotide (14F and F14 in Table 1,
respectively). As expected, the 30-ﬂuorescein-phospho-
diester bond of the 14F oligonucleotide was hydrolyzed
by human Tdp1 to generate the 30-phosphate-terminated
14-mer product (Figure 1A). However, this reaction was
less eﬃcient than the 30-phosphotyrosine substrate (14Y in
Table 1) (Figure 1A and D).
Having established that 30-ﬂuorescein is a substrate for
Tdp1, we tested whether Tdp1 could also process
50-ﬂuorescein-DNA (F14). Figure 1B shows that a single
cleavage product was observed with the F14 oligo-
nucleotide. However, this product exhibited a reduced
migration relative to the 50-phosphate-terminated marker
(Figure 1B), suggesting that Tdp1 is unable to simply
cleave the ﬂuorescein adduct linked to the 50-end of
DNA. Given that the TdT-mediated 30-end
32P-radio-
labeling of the F14 oligonucleotide leads to the addition
of a 30-terminal 30-deoxyadenosine (cordycepin), we con-
sidered the possibility that the detected cleavage product
may be a consequence of the 30-nucleosidase activity of
Tdp1. To establish the occurrence of this 30-nucleolytic
product, we utilized the 30-phosphatase activity of
polynucleotide kinase from bacteriophage T4 (PNK) to
show that the product of the Tdp1 reaction contained a
30-terminal
32P-radiolabel. As shown in Figure 1C, the
combination of Tdp1 and PNK resulted in the disappear-
ance of the product (compare lanes 3 and 5), which indi-
cates the removal of the 30-deoxynucleoside by Tdp1
followed by removal of the resulting 30-terminal
32P-radiolabel by PNK (Figure 1E). This result was
further corroborated in control reactions, which
employed a 30-phosphatase-minus T4 PNK mutant
[PNK
 ] (see lane 7). Similar results were obtained using
a5 0-biotin-DNA substrate (data not shown). Taken
together, these results demonstrate that human Tdp1 can
hydrolyze a 30-terminal phosphodiester-linked ﬂuorescein
or nucleoside leading to a 30-phosphate DNA end under
Nucleic Acids Research,2010, Vol.38, No. 7 2447conditions where it has no detectable activity towards a
50-terminal-phosphodiester-linked ﬂuorescein.
Fluorescence anisotropy analysis of binding of human
Tdp1 to ﬂuorescein-labeled oligonucleotides
To characterize the DNA binding properties of human
Tdp1 depending on the presence of ﬂuorescein at the 50-
or 30-end of the substrate, we measured changes in the
anisotropy of ﬂuorescein-labeled oligonucleotides upon
titration with Tdp1. Fluorescence anisotropy is a spectro-
scopic technique that monitors macromolecular associa-
tions predominantly through changes in the rotational
motion of ﬂuorescent molecules (25). As the molecular
weight of the ﬂuorophore increases, due to Tdp1–DNA
binding, the rotational freedom of the DNA is reduced,
leading to an increase in anisotropy (i.e. retention of polar-
ization). This is illustrated schematically in Figure 2A.
For these experiments, we employed the two
ﬂuorescein-labeled oligonucleotides previously employed
in the enzymatic activity assays (14F and F14) as well as
an additional 50-ﬂuorescein-labeled oligonucleotide con-
taining a 30-phosphate (Table 1, F14p), known not to be
hydrolyzed by Tdp1 (6). Figure 2B depicts the ﬂuorescent
anisotropy with increasing concentration of Tdp1. No
increase in anisotropy was observed with the 30-labeled
oligonucleotide (14F), which was anticipated, given that
Tdp1 hydrolyzes the 30-ﬂuorescein (Figure 1A). More
interestingly, we detected a concentration-dependent
enhancement in anisotropy for both 50-labeled oligo-
nucleotides (F14 and F14p). Based on calculated KD
values (Table 1), Tdp1 bound with an  3-fold higher
aﬃnity to F14p than it did to F14. There are two
possible explanations for this diﬀerence. First, Tdp1 may
bind better to a 30-phosphate as compared to a
30-hydroxyl; or second, Tdp1 may have a higher binding
aﬃnity for longer DNA sequences in vitro. The latter is
based on the fact that Tdp1 can hydrolyze 30-hydroxyl
ends (Figure 1B), which would result in a one base
shorter F13p oligonucleotide product. Consistent with
that explanation, previous studies have shown that Tdp1
is more eﬀective at processing DNA-peptide substrates
with a longer DNA component (4). Further support for
the DNA length dependent binding of human Tdp1 is
shown in Figure 2C, wherein Tdp1 shows a roughly
BC
A
Excitation
Light
Emitted
Light
F
F
Tdp1
Large molecule
Slow "tumbling"
Small molecule
Fast "tumbling"
Polarized
Polarized
Depolarized
High
Anisotropy
Low
Anisotropy
0.1 1 10 100 1000
0
0.05
0.1
0.15
0.2 14p
50p
0.1 1 10 100 1000
0
0.05
0.1
0.15
0.2
0.25
14F
F14
F14p
[Tdp1] (nM) [Competitor] (nM)
F
l
u
o
r
e
s
c
e
n
c
e
 
A
n
i
s
o
t
r
o
p
y
F
l
u
o
r
e
s
c
e
n
c
e
 
A
n
i
s
o
t
r
o
p
y
Figure 2. Equilibrium binding of recombinant human Tdp1 to ﬂuorescein-labeled oligonucleotides using ﬂuorescence anisotropy. (A) Schematic
diagram showing the principle of ﬂuorescence anisotropy. (B) Fluorescence anisotropic signal for 14F (ﬁlled squares), F14 (ﬁlled circles) and F14p
(open circles) as a function of Tdp1 concentration. Each point of the graph represents the mean (n=3) ±95% conﬁdence interval (error bars). (C)
Analysis of the competition between oligonucleotides in solution using ﬂuorescence anisotropy. Representative plots of Tdp1 binding competition
between F14p and unlabeled 14p (open circles) or 50p (ﬁlled diamonds).
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ing oligonucleotide as compared to a 14p oligonucleotide
using a ﬂuorescence anisotropy competition assay. These
results also suggest that Tdp1 does not have to initially
bind to the 30-end of the DNA. If Tdp1 was directly
binding the 30-end of the DNA, then one would expect
the binding curves to be indistinguishable given that
both oligonucleotides have a single 30-end available for
binding. Thus, these results imply that Tdp1 may initially
interact electrostatically with the DNA prior to reaching
its site of action (i.e. the 30-end).
30-end speciﬁc binding of human Tdp1 to a
non-hydrolyzable, phosphorothioate-linked
30-ﬂuorescein-containing oligonucleotide
Previous studies have demonstrated that guanosine
residues have the propensity to quench the ﬂuorescence
intensity of ﬂuorescein-oligonucleotide conjugates (25–7).
More speciﬁcally, it has been shown that the time-resolved
ﬂuorescence decay of a ﬂuorescein located proximal to a
guanosine residue in a single-stranded oligonucleotide is
ﬁtted to a bi-exponential function with two apparent
decay lifetimes (27). This indicates that the ﬂuorescein is
found in two distinct conformations. The longer lifetime
corresponds to an unquenched state or direct excitation of
the ﬂuorescein, whereas the shorter lifetime refers to a
quenched state or rapid charge transfer reaction between
the ﬂuorescein and the guanosine residue (Figure 3A).
Furthermore, the bi-exponential ﬁt allows for determina-
tion of the relative abundance or amplitude of the two
decay lifetimes.
To assess the end-speciﬁc binding of human Tdp1 using
the aforementioned guanosine quenching method, we
designed two oligonucleotides wherein a guanosine base
was placed adjacent to the 50-o r3 0-terminal ﬂuorescein.
We envisioned that if human Tdp1 possesses a 30-end
speciﬁc binding activity, then we would observe a
decrease in quenching, as Tdp1 would occlude the
30-ﬂuorescein from interacting with the adjacent guanosine
residue (Figure 3A).However, prior to testing our hypoth-
esis a non-hydrolyzable Tdp1 substrate had to be
developed given that Tdp1 readily removes a
phosphodiester-linked 30-ﬂuorescein (Figure 1A).
Phosphorothioate linkages are commonly used to reduce
oligonucleotide sensitivity toward nucleases. In addition,
phosphorothioate modiﬁcations have been used to study
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Figure 3. Binding and processing of phosphorothioate-linked ﬂuorescein containing oligonucleotides by recombinant human Tdp1. (A) Simpliﬁed
representation of the quenched and unquenched states of the terminal ﬂuorescein in the absence and presence of Tdp1. (B) Representative denaturing
PAGE gel showing the hydrolyzability and non-hydrolyzability of a 30-ﬂuorescein attached via a phosphodiester linkage (15F) and phosphorothioate
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Therefore, we reasoned that attaching the 30-ﬂuorescein
via a phosphorothioate linkage might result in a
non-hydrolyzable Tdp1 substrate, which subsequently
could be exploited for end-speciﬁc DNA binding studies.
As shown in Figure 3B, the phosphorothioate-linked
30-ﬂuorescein [15(pS)F] is resistant to Tdp1 hydrolysis
under conditions where Tdp1 is able to remove phospho-
diester-linked 30-ﬂuorescein (15F). These results enabled
us to use the phosphorothioate-linked 30- and
50-ﬂuorescein-labeled oligonucleotides [15(pS)F and
F(pS)15 in Table 1, respectively] as probes for the time-
resolved ﬂuorescence quenching studies. We observed a
concentration-dependent increase in the unquenched
state of the 30-ﬂuorescein upon titration with recombinant
human Tdp1. By contrast only minimally changes were
discerned for the 50-ﬂuorescein (Figure 3C, lower curve).
In addition, we found that the binding of Tdp1 to the
non-hydrolyzable, 30-ﬂuorescein-containing oligo-
nucleotide reached a plateau at a 1:1 molar ratio. These
results provide additional data on the distribution of
diﬀerent species in solution and are consistent with the
30-end DNA binding of human Tdp1.
Fluorescence anisotropy was then used to quantify the
binding of human Tdp1 to the ﬂuorescent probes. The
attachment of 50-ﬂuorescein via a phosphodiester or
phosphorothioate linkage produced similar Tdp1
binding [compare F15 and F(pS)15 in Figure 3D), which
was expected given that both oligonucleotides have iden-
tical 30-termini (i.e. 30-hydroxyl) (Table 1). Conversely,
binding of Tdp1 to the non-hydrolyzable 15(pS)F oligo-
nuceotide could now be detected by ﬂuorescence
anisotropy and was at least 10-fold more eﬃcient than
the 50-ﬂuorescein-linked oligonucleotides (Figure 3D and
KD values in Table 1). Taken together, these results
suggest that unnatural 30-adducts may create a high
aﬃnity binding site for human Tdp1.
Preferential binding of human Tdp1 to the 30-end
of DNA using SPR
To gain further evidence that human Tdp1 binds to the
30-end of DNA, we utilized SPR wherein oligonucleotides
were biotinylated at either the 50-o r3 0-end for end-speciﬁc
immobilization to a neutravidin-coated sensor chip (B14p
and p14B in Table 1). As shown in Figure 4A by the
increase in response units from the initial baseline, Tdp1
binds with high aﬃnity to the 50-biotin immobilized,
30-phosphate containing oligonucleotide (B14p) in a
concentration-dependent manner. The Tdp1 binding
kinetics to the B14p oligonucleotide could not be ﬁt
assuming a single association and dissociation rate
constant. The complex kinetics may be due to non-speciﬁc
binding of Tdp1 to the surface, kinetic heterogeneity in the
Tdp1 protein sample, or transport eﬀects. However, Tdp1
does form a stable complex with the B14p oligonucleotide
at each Tdp1 concentration (Figure 4A). This equilibrium
binding response can be ﬁt to a Langmuir binding model
assuming a 1:1 binding interaction (inset in Figure 4A)
with a KD value of 57nM (Table 1). In contrast, SPR
analysis of the oligonucleotide immobilized in the
opposite orientation (p14B) results in a complete loss of
Tdp1 DNA binding activity (Figure 4B), indicating
that the interaction between the DNA and Tdp1
requires an exposed 30-end. Given the previously described
ability of Tdp1 to hydrolyze 30-linked biotin adducts (6),
it is worth noting that the maintenance of the
immobilized oligonucleotides subsequent to assaying the
DNA binding activity of Tdp1 was ensured based on
reproducible binding of HIV nucleocapsid protein (data
not shown) (24).
DISCUSSION
DNA strand breaks are a frequent source of ‘blocking’
DNA ends that can impede essential biological processes
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Figure 4. Diﬀerential binding of recombinant human Tdp1 to 30- and 50-phosphate terminated oligonucleotides using SPR. SPR sensorgrams
showing the interaction of Tdp1 with the (A) B14p oligonucleotide and (B) p14B oligonucleotide (see sequences above). Nine successive 2-fold
dilutions of Tdp1 from 500nM were tested for each oligonucleotide. The inset in (A) shows the equilibrium binding of Tdp1 to B14p ﬁtted to the 1:1
Langmuir binding model.
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and which is involved in the initial processing of a subset
of these DNA ends as a prerequisite for further repair
(2,30). The removal of a variety of 30-end lesions is a
well-accepted enzymatic activity of both the human and
yeast Tdp1 proteins. However, the 50-processing activity
of Tdp1 has been less studied. In their initial discovery of
the yeast Tdp1 enzyme, Yang et al. (2) reported lack of an
associated 50-processing activity. Nevertheless, it has
recently been suggested that yeast Tdp1 participates in
the repair of Top2-mediated DNA damage (i.e.
50-DNA–peptide adducts) (‘Introduction’ section) (20,21).
In this report, we utilized 30- and 50-ﬂuorescein-labeled
(i.e. 6-FAM) oligonucleotides as Tdp1 substrates to
examine the end-speciﬁc binding and processing of
human Tdp1. Initially, we demonstrate that a
30-ﬂuorescein is an eﬃcient substrate for human Tdp1
(Figure 1A). It is worth noting that similar to Interthal
et al. (6), we have not yet encountered a
30-phosphodiester-linked chemical moiety, albeit physio-
logical or non-physiological, that is not hydrolyzed by
human Tdp1 in vitro. Yet, we show here that introduction
of a phosphorothioate is suﬃcient to completely block
Tdp1 enzymatic activity.
The broad 30-end speciﬁcity of Tdp1 is not surprising
given that minimal contacts beyond the terminal
30-phosphodiester are observed in the human Tdp1
co-crystal structure bound to a DNA–Top1-derived
peptide substrate mimic (31). However, this observation
does not account for the diﬀerences in processing eﬃ-
ciency of 30-lesions by Tdp1. For example,  10-fold
more enzyme is required to hydrolyze the 30-ﬂuorescein
as compared to a 30-phosphotyrosine linkage (Figure 1A
and D). Moreover, a considerable excess of enzyme,  50-
and 80-fold, is needed for removal of a 30-nucleoside (6)
and a 30-glycolate (5), respectively. Thus, additional
co-crystal structures are warranted to explain the diﬀeren-
tial activity of human Tdp1 toward diﬀerent 30-adducts.
Our ﬂuorescence anisotropy studies demonstrate higher
binding aﬃnity of human Tdp1 for unnatural 30-adducts
(i.e. ﬂuorescence) as compared to normal 30-nucleoside
(i.e. 30-hydroxyl) or 30-nucleotide (i.e. 30-phosphate) con-
taining oligonucleotides (Table 1 and Figures 2B and 3D).
These results are consistent with the preferential activity of
Tdp1 toward 30-blocking adducts over physiological DNA
ends.
The internal location of the 30-phosphotyrosyl bond
within a stalled full-length Top1–DNA complex is an
unmanageable substrate for Tdp1 (32). Proteosomal deg-
radation of Top1, which presumably results in enhanced
access of the 30-phosphotyrosyl bond, has been suggested
for Tdp1 action in vivo (33). Several studies have shown
that Tdp1 can hydrolyze 30-phosphotyrosyl-linked
peptides, however markedly less eﬃciently than a
30-phosphotyrosine (3,4,6). Thus, the 30-ﬂuorescein
substrate is a plausible surrogate for the physiological
Tdp1 substrates: Top1 polypeptide-linked DNA,
30-phosphoglycolates and 30-nucleosides. In addition,
30-phosphodiester-linked substrates, such as ﬂuorescein
and biotin (6), provide convenient ways to study Tdp1
binding and catalytic activities. Our ﬁnding that a
terminal 30-phosphorothioate-linked adducts (i.e. ﬂuores-
cein) imparts resistance to Tdp1 hydrolysis may also be of
use (Figure 3A).
While in agreement with the initial study from Yang
et al. (2), but in contrast to a more recent report regarding
yeast Tdp1 (20), we were unable to detect any processing
of a 50-ﬂuorescein by human Tdp1 (Figure 1B). We
extended this observation using both time-resolved ﬂuo-
rescence quenching (Figure 3C) and SPR (Figure 4B) to
demonstrate the inability of human Tdp1 to bind DNA
50-end. At the same time these biophysical techniques
provided strong and consistent evidence for strong
binding of human Tdp1 to DNA 30-ends. The diﬀerence
between the human enzyme [our results and ref. (2)] and
the yeast enzyme (20) regarding 50-ends might be due to
the diﬀerent substrates or speciﬁc activity of the enzymes
used. We cannot exclude the possibility that
50-peptide-DNA adducts might behave diﬀerently than
the ﬂuorescein or tyrosyl substrates, which are readily pro-
cessed when placed at the 30-end of DNA but not when
they are at the 50-end (present study). The published
results in ref. (21) are challenging to explain because the
processing of Top2 covalent complexes is poorly under-
stood (34). It is not excluded that Tdp1 could play a role
in processing the DNA ends following Top2 removal but
without being directly involved in hydrolyzing the Top2–
tyrosyl-DNA linkage.
In summary, the results presented here show converging
lines of evidence that the human Tdp1 protein
preferentially binds and processes the 30-ends of DNA.
The apparent lack of 50-end processing activity of
human Tdp1 is likely to be compensated by a complemen-
tary enzyme with 50-phosphodiesterase activity. A recent
report has discovered Tdp2 (TTRAP) as the enzyme that
carries out the 50-processing in human cells and plays a
role in the removal of Top2–DNA adducts as well as other
50-adducts (35).
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